Dr. Peter Faries, Chief of Vascular Surgery at Mount Sinai Hospital, and Dr. Brian DeRubertis, Associate Professor of Vascular Surgery at UCLA, discuss how innovative stent designs like Supera offer excellent clinical and economical benefits for patients, payers and providers.
Brian DeRubertis, MD, is an Associate Professor of Surgery in the Division of Vascular Surgery at the David Geffen School of Medicine at UCLA. He completed his bachelor’s degree in psychobiology at UCLA before moving to New York City for his medical training. He was awarded his M.D. degree from Cornell University Medical College in 1997, and then completed his general surgery residency training at the New York Presbyterian-Weill Cornell Medical Center in 2005. He then pursued specialty training in vascular and endovascular surgery through the combined Weill Medical College of Cornell University and Columbia University College of Physicians & Surgeons vascular fellowship. His research interests include the endovascular (minimally-invasive) treatment of lower extremity vascular disease and carotid artery disease.
Peter Faries, MD, FACS, is the Chief of Vascular Surgery at the Mount Sinai Hospital in New York and is an expert in the treatment of carotid artery disease for the prevention of stroke. Dr. Faries has helped advance the practice of minimally invasive vascular surgery, particularly the use of percutaneous techniques that can effectively improve arterial blood flow without the need for more invasive, traditional open surgery. His practice focuses on percutaneous transluminal angioplasty for the treatment of carotid artery stenosis, renovascular hypertension, and lower extremity ischemia, as well as endovascular treatments for thoracic and abdominal aortic aneurysms.